Practical Ways to improve patients' treatment outcomes - CORPORATE

Practical Ways to Improve Patients' Treatment Outcomes - CORPORATE

Volumn , Issue , 2009, Pages 1-92

  Feldman, Steven R ^a  

^a Wake Forest School of Medicine Winston Salem   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85074549945     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203092439     Document Type: Book

References (42)

1. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. "Poor adherence to treatments: a fundamental principle of dermatology." Arch Dermatol 143 (2007): 912-5.
2. Baldwin, Hilary E. "Tricks for improving compliance with acne treatment." Dermatologic Therapy 19 (2006): 224-36.
3. Balkrishan, Rajesh. "The Importance of Medication Adherence in Improving Chronic-Disease Related Outcomes: What We Know and What We Need to Further Know." Medical Care 43 (2005): 517-20.
4. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. "Electronic monitoring of medication adherence in skin disease: results of a pilot study." JAm Acad Dermatol49 (2003): 651-4.
5. Barankin, Benjamin. Dermographies: Autobiographies in Dermatology, Volume 2. Nova Scotia, Canada: Community Books, 2006.
6. Beutner K, Chakrabarty A, Lemke S, Yu K. "An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis." J Drugs Dermatol5 (2006): 356-60.
7. Bolognia J, Jorizzo JL, Rapini RP. Dermatology. New York: Mosby, 2003.
8. Brown KK, Rehmus WE, Kimball AB. "Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis." JAm Acad Dermatol55 (2006): 607-13.
9. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. "Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment." Arch Dermatol141 (2005): 43-6.
10. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. "Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use." JAm Acad Dermatol 51 (2004): 212-6.
11. Cork MJ, Britton J, Butler L, YoungS, Murphy R, Keohane SG. "Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse." Br J Dermatol149 (2003): 582-9.
12. Ersser SJ, Latter S, Sibley A, Satherley PA, Welbourne S. "Psychological and educational interventions for atopic eczema in children." Cochrane Database Syst Rev, 2007: CD004054.
13. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R . " Adherence to topical therapy increases around the time of office visits.'' JAm Acad Dermatol 57 (2007): 81-3.
14. Feldman SR, Dempsey JR, Grummer S, Chen JG, Fleischer AB. "Implications of a utility model for ultraviolet exposure behavior." JAm Acad Dermatol. 45 (2001): 718-22.
15. Feldman, Steven R. "Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: Add-on therapy in the COBRA trial." Cutis 80 (suppl 5) (2007): 20-28.
16. Fleischer, AB Jr. "Black box warning for topical calcineurin inhibitors and the death of common sense." Dermatol Online J 12 (2006): 2.
17. Franz TJ, Lehman PA, Feldman SR, Spellman MC. "Bioavailability of clobetasol propionate in different vehicles." Skin Pharmacal Appl Skin Physio l16 (2003): 212-6.
18. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. "Risk of myocardial infarction in patients with psoriasis." lAMA 296 (2006): 1735-41.
19. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. "The risk of lymphoma in patients with psoriasis." J Invest Dermatol 126 (2006): 2194-201.
20. Habif, TP. Psoriasis and other papulosquamous diseases. Clinical dermatology :a color guide to diagnosis and therapy. Philadelphia: Mosby, 2004.
21. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR. "The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis." JAm Acad Dermatol 49 (2003): 79-82.
22. Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. "Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference." Cutis 70 (2002): 327-32.
23. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. "Ciobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis." J Drugs Dermatol 3 (2004): 367-73.
24. Krejci-Manwaring J, Johnson KP, McCarty MA, Carroll CL, Hartle J, Manuel J, Balkrishnan R, Fleischer A Jr, Feldman SR. "Comparison of different compliance behaviors in a clinical trial." Cutis 79 (2007): 379-81.
25. Krejci-Manwaring J, Mccarty MA, Camacho F, Carroll CL, Johnson K, Manuel J, Balkrishnan R, Hartle J, Fleischer A Jr, Feldman SR. "Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents." J Am Acad Dermatol 54 (2006): S235-6.
26. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer ABJr, Balkrishnan R, Feldman SR. "Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis." JAm Acad Dermatol 56 (2007): 211-6.
27. Lebwohl M, Colon LE. "The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis." Cutis 80 (suppl 5) (2007): 29-40.
28. Maibach HI, Stoughton RB. "Topical corticosteroids." Med Clin North Am 57 (1973): 1253-64.
29. Marks VJ, Hutchison R, Todd M. "Service excellence in dermatology." Semin Cutan Med Surg 23 (2004): 207-12.
30. Menter, Alan. "Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial." Cutis 80 (suppiS) (2007): 12-19.
31. Nelms, Henning. Magic and Showmanship: A Handbook for Conjurers. Mineola, New York: Dover Publications, Inc, 1969.
32. Reid DC, Kimball AB. "Ciobetasol propionate foam in the treatment of psoriasis." Expert Opin Pharmacother 6 (2005): 1735-40.
33. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. "Patients with psoriasis and their compliance with medication." JAm Acad Dermatol 41 (1999): 581-3.
34. Rook A, Burns T, Breathnach S, Cox N, Griffiths C. Rook's textbook of dermatology. 2004.
35. Rowlands CG, Danby FW. "Histopathology of psoriasis treated with zinc pyrithione." Am J Dermatopathol 22 (2000): 272-6.
36. Rubin, Bruce. "What Does It Mean When a Patient Says, "My Asthma Medication Is Not Working"?" Chest 126 (2004): 972-981.
37. Shelley W, Shelley D. "A dermatologic diary. Portrait of a practice." Cutis, 1997.
38. Smith, K. "Skin Cap: what have we learned, and when did we learn it?" Dermatol Online J 3 (1997): llc.
39. Stein, L. "Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis." J Am Acad Dermatol 53 (2005): S39-49.
40. Swanson DL, Pittelkow MR, Benson LM, Hawkridge AM, Muddiman DC. "Deja vu all over again: skin cap still contains a high-potency glucocorticosteroid." Arch Dermatol 141 (2005): 801-3.
41. Warino L, Balkrishnan R, Feldman SR. "Ciobetasol propionate for psoriasis: are ointments really more potent?" J Drugs Dermatol 5 (2006): 527-32.
42. Zaghloul SS, Goodfield MJ. "Objective assessment of compliance with psoriasis treatment." Arch Dermatol l40 (2004): 408-14.